Drug Trial Radar · NCT07888699
WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Oct 15, 2027
Study completion Dec 25, 2027
Sponsor
- Lead sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 150 pre-menopausal women with bacterial vaginosis (BV). Participants will be randomized 1:1:1 to three groups. All participants will receive oral metronidazole 0.4 g twice daily for 7 days. In addition, participants will take vaginal capsules (high-dose WST03, low-dose WST03, or matched placebo) once daily for 14 days. The primary endpoint is cumulative BV recurrence rate at Week 12. This trial evaluates the efficacy and safety of WST03 plus metronidazole for lowering BV recurrence and explores its impact on vaginal microecology.
Conditions
- Bacterial Vaginosis (BV)
Interventions
High-dose WST03 Vaginal Capsule MetronidazoleDrug
High-dose vaginal capsule containing multi-strain live lactobacilli; vaginal administration, once daily for 14 consecutive days (Day 1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).
Low-dose WST03 Vaginal Capsule MetronidazoleDrug
Low-dose vaginal capsule containing multi-strain live lactobacilli; vaginal administration, once daily for 14 consecutive days (Day 1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).
Placebo Vaginal Capsule MetronidazoleDrug
Placebo vaginal capsule, visually identical to WST03 capsule, vaginal administration, once daily for 14 consecutive days (Day1-14). Metronidazole 0.4 g twice daily for 7 days (Day1-7).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative recurrence rate of bacterial vaginosis (BV) up to Week-12 visitTime frame: From first study drug administration up to Week-12 visit
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Shenzhen University of Technology General Hospital
Shenzhen, Guangdong, China
Liuzhou Maternal and Child Health Hospital
Liuzhou, Guangxi, China
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan, China
Taihe Hospital, Shiyan City
Shiyan, Hubei, China
Zhuzhou Maternal and Child Health Hospital
Zhuzhou, Hunan, China
The Second Hospital of Jilin University
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China
Women's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.